Altimmune (ALT) Accumulated Expenses (2010 - 2026)

Altimmune (ALT) has reported Accumulated Expenses for 17 consecutive years, with $9.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 12.29% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $9.8 million (up 12.29% YoY), while the FY2025 annual figure was $12.3 million, up 19.72% from the prior year.
• Accumulated Expenses declined to $9.8 million in Q1 2026 per ALT's latest filing, from $12.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $12.6 million in Q1 2022 and bottomed at $48000.0 in Q3 2022.
• Historically, Accumulated Expenses has averaged $6.2 million across 5 years, with a median of $7.5 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 99.75% — and 2023, when it soared 15006.12%.
• Altimmune's Accumulated Expenses stood at $12.2 million in 2022, then retreated by 17.77% to $10.1 million in 2023, then rose by 1.83% to $10.3 million in 2024, then increased by 19.72% to $12.3 million in 2025, then slipped by 20.25% to $9.8 million in 2026.
• Business Quant data shows ALT's Accumulated Expenses at $9.8 million in Q1 2026, $12.3 million in Q4 2025, and $2.4 million in Q3 2025.